Darlene Staines

Goodwin

Contact
View Bio
RSS

Latest Posts › Contract Terms

Share:

Harrow Enters Agreement to Commercialize Samsung Bioepis’s Ophthalmology Biosimilars Following Biogen’s Exit

On July 17, 2025, Harrow, Inc. (“Harrow”), announced an agreement with Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) to acquire the U.S. commercial rights to two of Samsung Bioepis’s biosimilars, BYOOVIZ® (ranibizumab-nuna)...more

7/30/2025  /  Biosimilars , Biotechnology , Contract Terms , FDA Approval , Intellectual Property Protection , Pharmaceutical Industry , Pharmaceutical Patents , Prescription Drugs , Samsung Bioepis
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide